Arcus Biosciences(RCUS) - 2024 Q4 - Annual Report

Financial Performance - Total revenues for 2024 increased to $258 million, a 121$117 million in 2023, primarily driven by a $107 million revenue catch-up from the Gilead collaboration [386]. - License and development service revenue for 2024 was$222 million, reflecting a significant 178% increase from $80 million in 2023 [385]. - Total operating expenses for 2024 were$588 million, a 29% increase from $457 million in 2023 [441]. - Net loss for 2024 was$283 million, a slight improvement from a net loss of $307 million in 2023 [443]. - Revenue recognized under the Gilead Agreements for the year ended December 31, 2024, was$243 million, with $215 million recognized when services were performed [439]. - The company recognized a cumulative catch-up revenue of$107 million in 2024 due to a contract modification with Gilead, which reduced net loss per share by $1.19 [523]. - The company reported a basic and diluted net loss per share of$3.14 for 2024, improving from $4.15 in 2023 [441]. - Loss before income taxes for the year ended December 31, 2024, was$282 million, compared to $301 million in 2023 [553]. Cash and Investments - As of December 31, 2024, the company had$992 million in cash, cash equivalents, and marketable securities, which, along with recent equity financing, is expected to fund operations for the foreseeable future [372]. - Cash and cash equivalents at the end of 2024 were $150 million, up from$127 million at the end of 2023 [446]. - Marketable securities increased to $828 million in 2024, compared to$632 million in 2023, representing a 31% increase [446]. - Cash flow from operating activities for 2024 was a net outflow of $170 million, compared to a net outflow of$306 million in 2023 [451]. - Cash used in investing activities for 2024 was $78 million, mainly from net purchases of marketable securities, while cash provided in 2023 was$218 million from net proceeds of marketable securities [410]. - Cash used in financing activities for 2024 included net proceeds of $228 million from the issuance of common stock to Gilead under the Third Stock Purchase Agreement Amendment [412]. - The company had cash, cash equivalents, and marketable securities of$992 million as of December 31, 2024, compared to 866 million in 2023 [426]. Research and Development - The company has a robust portfolio of investigational products, with its most advanced molecule, an anti-TIGIT antibody, currently in multiple Phase 3 registrational studies targeting lung and GI cancers [356]. - The company expects substantial increases in R&D expenses as it advances joint development programs with Gilead and prepares for regulatory approvals [379]. - Research and development expenses rose to 448 million in 2024, a 32% increase from 340 million in 2023, driven by late-stage development program activities [390]. - R&D expenses include costs for clinical studies, with significant components being third-party service provider costs [468]. - The company recognizes revenue from research, collaboration, and license arrangements, with no product sales reported [461]. Collaborations and Agreements - The company has not generated any revenue from product sales and does not expect to do so in the foreseeable future, relying instead on collaboration and license agreements [373]. - Gilead made an upfront payment of 175 million upon closing the initial collaboration agreement in 2020, and a total payment of $725 million for three programs in 2022 [491]. - In 2024, Gilead purchased 15.2 million shares for total gross proceeds of$320 million, with $87 million allocated as deferred revenue [487]. - The company entered into multiple amendments to the Gilead Collaboration Agreement, enhancing strategic partnerships [483]. - The company is contractually obligated to make significant payments upon achieving various development, regulatory, and commercial milestones, which are contingent on uncertain future events [415]. - The company recognized$28 million, $33 million, and$33 million in other collaboration revenue for the years ended December 31, 2024, 2023, and 2022, respectively [542]. Expenses and Liabilities - General and administrative expenses increased to $120 million in 2024, a 3$117 million in 2023, attributed to the complexity of supporting an expanding clinical pipeline [392]. - Impairment charges for long-lived assets amounted to $20 million in 2024, compared to no impairment in the previous year [394]. - The company had outstanding debt with a carrying value of$48 million as of December 31, 2024, bearing interest at a rate equal to the greater of 10.45% or the prime rate plus 1.95% [427]. - The company recognized a total liability of $26 million related to obligations to AstraZeneca as of December 31, 2024 [514]. Market and Risk Factors - The company is exposed to foreign currency exchange rate risk, but a hypothetical 20% adverse movement would not result in a material impact on its financial position or income [428]. - The effective tax rate for 2024 was impacted by a change in valuation allowance, resulting in a rate of (28.1)% [554].